Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial
oleh: Paul G. Richardson, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung‐Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi‐Ankrah, Richard Labotka, Robert M. Rifkin, Sagar Lonial, Shaji K. Kumar, S. Vincent Rajkumar, Philippe Moreau
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2023-11-01 |
Deskripsi
Abstract Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression‐free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0–4 months; n = 424) versus late responders (best confirmed response >4 months; n = 281). Newly diagnosed patients enrolled in TOURMALINE‐MM2 receiving ixazomib‐lenalidomide‐dexamethasone (IRd) (n = 351) or placebo‐Rd (n = 354) were evaluated post hoc. Deeper responses were associated with longer PFS (complete response [CR] not reached [NR], very good partial response [VGPR] 37.2 months, partial response [PR] 16.4 months) and DOR (CR NR, VGPR 42.6 months, PR 15.4 months). Among patients with a PFS (n = 511) or DOR (n = 484) of ≥6 months who achieved ≥PR, median PFS was prolonged among late versus early responders receiving IRd (59.7 vs. 17.9 months) or placebo‐Rd (56.6 vs. 12.4 months), as was median DOR (IRd, NR vs. 20.9 months; placebo‐Rd, 58.2 vs. 11.7 months). While the treatment paradigm for newly diagnosed MM is treatment to progression, our findings suggest slowness of response to a proteasome inhibitor‐immunomodulatory drug‐steroid combination is not a negative predictor of outcome.